According to a new report by Polaris Market Research, the global oncology-based molecular diagnostics market was valued at USD 3.66 billion in 2024 and is projected to reach USD 6.12 billion by 2034, expanding at a CAGR of 5.3% over the forecast period. Growth is underpinned by rising cancer incidence worldwide, expanding adoption of precision oncology testing, and accelerating advances in next-generation sequencing and liquid biopsy platforms across key end-use industries.

What Is Driving Oncology-Based Molecular Diagnostics Market Growth?

Demand is climbing as the rising global cancer burden converges with rapid advancements in molecular oncology testing technology. Healthcare systems and diagnostic manufacturers are prioritizing early and precise detection tools, pushing oncology-based molecular diagnostics adoption across hospital laboratories, reference labs, and specialty cancer centers. Polaris analysts note that a February 2024 World Health Organization projection of 35 million global cancer cases by 2050 — a 77% increase over 2022 levels — positions the market for sustained growth through 2034, with reagents emerging as the largest revenue contributor and sequencing-based platforms posting the fastest incremental gains.

Key Trends Shaping the Oncology-Based Molecular Diagnostics Industry

AI-Enabled Precision Oncology

Artificial intelligence is reshaping cancer diagnostics by matching patients to therapies based on their molecular profiles and enabling faster treatment decisions. AI-driven analysis of genomic and imaging data is helping clinicians flag malignancies earlier, while machine-learning models that forecast recurrence risk and disease progression are becoming embedded in routine oncology workflows, supporting broader technology advancement across the sector.

Next-Generation Sequencing and Liquid Biopsy Innovation

Innovation in next-generation sequencing (NGS), liquid biopsy, and multiplex PCR is expanding the range, speed, and accuracy of cancer detection and monitoring. Roche's February 2025 launch of its Sequencing by Expansion (SBX) technology illustrates how new chemistry and sensor combinations are enabling deeper genomic analysis, reinforcing the sector's regulatory landscape and clinical-adoption momentum.

Rising R&D Investment and Funding Activity

Capital is flowing into assay development and diagnostic-platform innovation as investors back multiomics and blood-based cancer screening. Freenome's USD 254 million raise in February 2024 to advance multiomics blood tests for early and multi-cancer detection reflects a broader market outlook in which funding activity is accelerating clinical integration and regulatory approval for oncology-based molecular diagnostics.

Market Segmentation: Breaking Down the Oncology-Based Molecular Diagnostics Market

Polaris segments the oncology-based molecular diagnostics market by cancer type, product, technology, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Type

The breast cancer segment led the market in 2024, accounting for 18.69% of revenue, on the strength of high disease prevalence, widespread screening programs, and well-established tests for hormonal and genetic markers such as HER2 and BRCA mutations. Lung, colorectal, and blood cancer segments are drawing increasing test volumes as broader oncology screening panels and multi-cancer detection assays expand clinical use beyond the traditionally dominant cancer type.

By Product

Reagents remain the dominant product category, capturing 58.61% of revenue in 2024, driven by their recurring, per-test consumption across PCR, sequencing, and hybridization workflows. Instruments — a smaller, largely one-time capital purchase — continue to underpin laboratory capacity expansion, signaling where near-term demand for automated, high-throughput testing platforms is shifting.

By Technology

The sequencing segment is projected to expand at the fastest pace through 2034, reflecting its ability to deliver detailed, high-resolution cancer genomic insights. Next-generation sequencing supports the simultaneous analysis of multiple genes and mutations tied to tumor development, making it increasingly central to identifying actionable therapeutic targets and resistance mechanisms as personalized treatment regimens gain ground.

Regional Outlook: Where Is the Oncology-Based Molecular Diagnostics Market Growing Fastest?

North America led the market in 2024 with a 44.69% share, supported by advanced healthcare infrastructure, a deep research ecosystem, and early adoption of innovative diagnostic technologies, while Asia Pacific is expected to post the fastest CAGR through 2034, driven by supportive regulations, rising diagnostic standards, and growing demand for personalized cancer care. Within North America, the U.S. remains the largest single market on the strength of its R&D capabilities and reimbursement infrastructure; within Asia Pacific, India is emerging as a key growth engine as screening access expands across urban and semi-urban regions. Europe rounds out the top three, supported by strong regulatory frameworks and cross-border clinical research collaboration.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/oncology-based-molecular-diagnostics-market 

Competitive Landscape: Leading Oncology-Based Molecular Diagnostics Companies

Key players profiled in the report include F. Hoffmann-La Roche Ltd., Abbott, Qiagen, and Agilent Technologies, Inc., who are focusing on platform launches, capacity expansion, and strategic partnerships to strengthen market position across the reagents and sequencing segments outlined above. Recent moves include Illumina's May 2025 expansion of its clinical oncology portfolio with new tumor-profiling and IVD solutions, and an August 2024 partnership between Hitachi High-Tech and Gencurix to develop cancer molecular diagnostics and commercialize testing services in Japan — both aimed at deepening share across North America and Asia Pacific.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the oncology-based molecular diagnostics market, this report benchmarks market share, segment-level pricing, and forecast data — by type, product, technology, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking sequencing-based platforms as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Christmas Decoration Market

Artificial Intelligence (AI) in Military Market

Connected Worker Market

Pad-mounted Switchgear Market

Artificial Intelligence (AI) in Military Market

Solar Panels Market

Blockchain Technology In The Energy Sector Market

Liver Metastases Treatment Market: An Acute Cancer Treatment to Cure with Effective Mediation

U.S. Premium Bottled Water Market